Quest PharmaTech Inc. (CVE:QPT – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 7000 shares. The stock had previously closed at C$0.04.
Quest PharmaTech Stock Performance
The company has a debt-to-equity ratio of 1.51, a current ratio of 0.26 and a quick ratio of 0.52. The firm has a fifty day moving average price of C$0.03 and a two-hundred day moving average price of C$0.04. The stock has a market capitalization of C$3.38 million, a PE ratio of -0.17 and a beta of 0.29.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Read More
- Five stocks we like better than Quest PharmaTech
- The How And Why of Investing in Oil Stocks
- Hasbro’s Management Made All the Right Calls This Quarter
- Do ETFs Pay Dividends? What You Need to Know
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to Calculate Inflation Rate
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
